17th North American Regional ISSX Meeting (October 16 - 20, 2011): Non-P450 Phase I Enzymes

P262

An Investigation Into The Prediction Of In Vivo Clearance For A Range Of Aldehyde Oxidase Substrates Using A Mechanistic Population-Based Pharmacokinetic Model
Helen Cubitt, Simcyp Ltd; Karen Rowland-Yeo, Simcyp Ltd; Amin Rostami-Hodjegan, Simcyp Limited and The University of Manchester; Zoe Barter, Simcyp Ltd

P263

Characterization Of Hydralazine As A Specific Aldehyde Oxidase Inhibitor To Assess Fraction Metabolized In Human Hepatocytes
Christine C. Orozco, Pfizer; Timothy J. Strelevitz, Pfizer; Ronald S. Obach, Pfizer

P264

Characterization of Aldehyde Oxidase (AO) Activity in Cryopreserved Human Hepatocytes
James Matthew Hutzler, Boehringer-Ingelheim Pharmaceuticals; Young-Sun Yang, Boehringer-Ingelheim Pharmaceuticals; Daniel Albaugh, Boehringer-Ingelheim Pharmaceuticals; Cody Fullenwider, Boehringer-Ingelheim Pharmaceuticals; Diane Wong, Boehringer-Ingelheim Pharmaceuticals; Jennie Schmenk, Boehringer-Ingelheim Pharmaceuticals; Michael Fisher, Boehringer-Ingelheim Pharmaceuticals

P265

Novel Human Hydrolase Carboxymethylenebutenolidase (CMBL): A Bioactivating Enzyme of Prodrug-type ARB Olmesartan Medoxomil
Tomoko Ishizuka, Daiichi Sankyo Co., Ltd.; Izumi Fujimori, Daiichi Sankyo Co., Ltd.; Mitsunori Kato, Daiichi Sankyo Co., Ltd.; Motoko Saito, Daiichi Sankyo Co., Ltd.; Yasushi Yoshigae, Daiichi Sankyo Co., Ltd.; Kazuishi Kubota, Daiichi Sankyo Co., Ltd.; Atsushi Kurihara, Daiichi Sankyo Co., Ltd.; Takashi Izumi, Daiichi Sankyo Co., Ltd.

P266

Quantitative Targeted Absolute Proteomics (QTAP) for the Analysis of UGT1As and UGT2Bs in Human Liver and Intestinal Microsomes using nanoUPLC-MS/MS with Selected Reaction Monitoring
Philip C. Smith, University of North Carolina at Chapel Hill; John K. Fallon, University of North Carolina at Chapel Hill; Hendrik Neubert, Pfizer; Ruth Hyland, Pfizer Inc.

P268

Strategic use of EDTA-free Subcellular Fractions for Better IVIVC in Early Drug Discovery
Liling Liu, Hoffmann-La Roche Inc.; Karl B. Frank, Hoffmann-La Roche Inc.; Adrian J. Fretland, Hoffmann-La Roche Inc.; Barry Goggin, Hoffmann-La Roche Inc.; David Moore, Hoffmann-La Roche Inc.; Rob T. Taylor, Hoffmann-La Roche Inc.

P269

Underestimation of the bioavailability of Aldehyde Oxidase substrates, example of FK3453. Is there a good strategy to predict AO clearance?
Nicolas Gerst, Astellas Rsch Inst of America; Takafumi Akabane, Astellas Rsch Inst of America; Bindu Upadhyay, Astellas Rsch Inst of America; Jeffrey Masters, Astellas Rsch Inst of America; Kouichi Tamura, Astellas Rsch Inst of America

P297

Targeting the PI3K Pathway in the Brain – Pharmacokinetics and Efficacy of a PI3K Inhibitor Optimized to Cross the Blood-Brain Barrier
Laurent Salphati, Genentech Inc.; Jodie Pang, Genentech Inc.; Jonathan Cheong, Genentech Inc.; Emile G. Plise, Genentech Inc.; Bruno Alicke, Genentech Inc.; Xiao Ding, Genentech Inc.; Jennafer Dotson, Genentech Inc.; Dingzhou Feng, Genentech Inc.; Tim Heffron, Genentech Inc.; Allan Joachico, Genentech Inc.; Leslie B. Lee, Genentech Inc.; Chudi Ndubaku, Genentech Inc.; Merry Nishimura, Genentech Inc.; Jim Nonomiya, Genentech Inc.; Alan Olivero, Genentech Inc.; Heidi Phillips, Genentech Inc.; Setve Sideris, Genentech Inc.; Lan Wang, Genentech Inc.; Xiaolin Zhang, Genentech Inc.